A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.

被引：1

作者：

Shitara, Kohei

Bang, Yung-Jue

Chung, Hyun Cheol

Yabusaki, Hiroshi

Iwasa, Satoru

Sakai, Daisuke

Muro, Kei

Sugimoto, Naotoshi

Yasui, Hisateru

Gamoh, Makio

Murakawa, Yasuko

Negoro, Yuji

Nishina, Tomohiro

Hosaka, Hisashi

Omuro, Yasushi

Kawaguchi, Yoshinori

Sugihara, Masahiro

Saito, Kaku

Dalal, Rita

Yamaguchi, Kensei

机构：

[1] Natl Canc Ctr Hosp East, Chiba, Japan

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Yonsei Canc Ctr, Seoul, South Korea

[4] Niigata Canc Ctr Hosp, Niigata, Japan

[5] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[6] Osaka Univ Hosp, Osaka, Japan

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Osaka Int Canc Inst, Osaka, Japan

[9] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan

[10] Osaki Citizen Hosp, Osaki, Japan

[11] Miyagi Canc Ctr, Natori, Miyagi, Japan

[12] Kochi Hlth Sci Ctr, Kochi, Japan

[13] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[14] Gunma Prefectural Canc Ctr, Ota, Japan

[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[16] Daiichi Sankyo Co Ltd, Tokyo, Japan

[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[18] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.TPS180

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS180

引用

页数：2

共 50 条

[21] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Fuchs, Charles S.
Shahidi, Javad
Mathew, Lijoy
Qin, Amy
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[22] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev A.
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[23] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev A.
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
Modi, Shanu
Ohtani, Shoichiro
Lee, Caleb
Wang, Yibin
Saxena, Kapil
Cameron, David A.
CANCER RESEARCH, 2020, 80 (04)
[25] Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Hamilton, Erika
Galsky, Matthew D.
Ochsenreither, Sebastian
Del Conte, Gianluca
Martin, Miguel
De Miguel, Maria Jose
Yu, Evan Y.
Williams, Anja
Gion, Maria
Tan, Antoinette R.
Agrawal, Laila
Rutten, Annemie
Machiels, Jean-Pascal
Cresta, Sara
Debruyne, Philip R.
Hennequin, Audrey
Moreno, Victor
Minchom, Anna
Valdes-Albini, Frances
Petrylak, Daniel
Li, Li
Tsuchihashi, Zenta
Suto, Fumitaka
Cheng, Fu-Chih
Kandil, Maha
Barrios, Daniel
Hurvitz, Sara
CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5548 - 5558
[26] A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.
Baselga, Jose
Tamura, Kenji
Yamashita, Toshinari
Modi, Shanu
Tokunaga, Eriko
Ito, Yoshinori
Iwata, Hiroji
Charif, Mahmoud
Lee, Caleb C.
Sugihara, Masahiro
Jikoh, Takahiro
Andre, Fabrice
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Nakada, Takashi
Sugihara, Kiyoshi
Jikoh, Takahiro
Abe, Yuki
Agatsuma, Toshinori
CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (03) : 173 - 185
[28] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
Meric-Bernstam, F.
Anoka, C.
Dobrowolska, A.
Chaudhry, A.
Rowbottom, J.
Gustavson, M.
Puvvada, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1253 - S1254
[29] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
Modi, S.
Tsurutani, J.
Tamura, K.
Park, H.
Sagara, Y.
Murthy, R.
Iwata, H.
Krop, I. E.
Doi, T.
Redfern, C.
Moreno-Aspitia, A.
Redman, R.
Lee, C.
Sugihara, M.
Fujisaki, Y.
Takahashi, S.
CANCER RESEARCH, 2019, 79 (04)
[30] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
Shitara, Kohei
Bang, Yung-Jue
Iwasa, Satoru
Sugimoto, Naotoshi
Ryu, Min-hee
Sakai, Daisuke
Chung, Hyun Cheol
Kawakami, Hisato
Yabusaki, Hiroshi
Lee, Jeeyun
Saito, Kaku
Kawaguchi, Yoshinori
Kamio, Takahiro
Kojima, Akihito
Sugihara, Masahiro
Yamaguchi, Kensei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →